A genome-wide association, polygenic risk score and sex study on opioid use disorder treatment outcomes
Abstract Opioid use disorder continues to be a health concern with a high rate of opioid related deaths occurring worldwide. Medication Assisted Treatments (MAT) have been shown to reduce opioid withdrawal, cravings and opioid use, however variability exists in individual’s treatment outcomes. Sex-s...
Main Authors: | Alannah McEvoy, Caroul Chawar, Amel Lamri, Jacqueline Hudson, Luciano Minuzzi, David C. Marsh, Lehana Thabane, Andrew D. Paterson, Zainab Samaan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-49605-0 |
Similar Items
-
Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences.
by: Caroul Chawar, et al.
Published: (2021-01-01) -
Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens
by: Alannah McEvoy, et al.
Published: (2025-06-01) -
The future of precision medicine in opioid use disorder: inclusion of patient-important outcomes in clinical trials
by: Nitika Sanger, et al.
Published: (2020-06-01) -
Assessing fragility of statistically significant findings from randomized controlled trials assessing pharmacological therapies for opioid use disorders: a systematic review
by: Leen Naji, et al.
Published: (2024-04-01) -
The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment
by: Ieta Shams, et al.
Published: (2019-11-01)